Related Experiment Video
Updated: Jun 24, 2026

Application of Genetically Encoded Fluorescent Nitric Oxide (NO•) Probes, the geNOps, for Real-time Imaging of NO• Signals in Single Cells
Published on: March 16, 2017
Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid leukemia cells
Jie Liu1, Swati Malavya, Xueqian Wang
1Inorganic Carcinogenesis Section, Laboratory of Comparative Carcinogenesis, National Cancer Institute at NIEHS, Research Triangle Park, NC, USA. Liu6@niehs.nih.gov
Abstract:
The nitric oxide (NO) prodrug JS-K is shown to have anticancer activity. To profile the molecular events associated with the anticancer effects of JS-K, HL-60 leukemia cells were treated with JS-K and subjected to microarray and real-time RT-PCR analysis. JS-K induced concentration- and time-dependent gene expression changes in HL-60 cells corresponding to the cytolethality effects. The apoptotic genes (caspases, Bax, and TNF-alpha) were induced, and differentiation-related genes (CD14, ITGAM, and VIM) were increased. For acute phase protein genes, some were increased (TP53, JUN) while others were suppressed (c-myc, cyclin E). The expression of anti-angiogenesis genes THBS1 and CD36 and genes involved in tumor cell migration such as tissue inhibitors of metalloproteinases, were also increased by JS-K. Confocal analysis confirmed key gene changes at the protein levels. Thus, multiple molecular events are associated with JS-K effects in killing HL-60, which could be molecular targets for this novel anticancer NO prodrug.
Insights
The anticancer drug JS-K triggers cell death in leukemia by altering gene expression. It activates apoptosis and differentiation pathways, offering potential molecular targets for novel nitric oxide (NO) prodrug therapies.
Area of Science:
- Molecular Biology
- Pharmacology
- Cancer Research
Background:
- Nitric oxide (NO) prodrugs represent a promising class of anticancer agents.
- JS-K has demonstrated anticancer activity, necessitating a deeper understanding of its molecular mechanisms.
- HL-60 leukemia cells are a relevant model for studying cytotoxic effects.
Purpose of the Study:
- To elucidate the molecular events underlying the anticancer effects of the NO prodrug JS-K.
- To identify specific gene expression changes induced by JS-K in HL-60 leukemia cells.
- To explore potential molecular targets for JS-K-based cancer therapies.
Main Methods:
- HL-60 leukemia cells were treated with varying concentrations and durations of JS-K.
- Microarray analysis was employed to profile global gene expression changes.
- Real-time RT-PCR and confocal microscopy were used to validate key gene and protein expression alterations.
Main Results:
- JS-K induced concentration- and time-dependent changes in gene expression, correlating with cytolethality.
- Upregulation of apoptotic genes (caspases, Bax, TNF-alpha) and differentiation markers (CD14, ITGAM, VIM) was observed.
- Modulation of acute phase protein genes (TP53, JUN, c-myc, cyclin E), anti-angiogenesis genes (THBS1, CD36), and tumor cell migration inhibitors was confirmed.
- Confocal analysis validated key molecular changes at the protein level.
Conclusions:
- JS-K exerts its anticancer effects through a multifaceted molecular mechanism involving apoptosis and differentiation.
- The observed gene expression changes highlight potential molecular targets for novel nitric oxide prodrug therapies.
- JS-K represents a promising novel anticancer NO prodrug with diverse molecular effects on leukemia cells.
Related Concept Videos
Nitric Oxide Signaling Pathway
Differentiation of Common Myeloid Progenitor Cells
Reporter Genes
Commonly used reporter...

